Lumera Adds Executive Talent With the Additions of Biotech Veteran Jim Richey and Bioanalysis and Nanotechnology Expert Dr. Charles T. Campbell

Jan 20, 2005, 00:00 ET from Lumera Corporation

    BOTHELL, Wash., Jan. 20 /PRNewswire-FirstCall/ -- Lumera Corporation
 (Nasdaq:   LMRA), an emerging leader in nanotechnology solutions, named Jim
 Richey as Senior Advisor, Business Development and named Dr. Charles T.
 Campbell to its scientific advisory board.
      "The addition of Jim Richey and Dr. Charles Campbell significantly
 enables our ability to bring new, revolutionary products to market," said Tom
 Mino, chief executive officer.  "We are committed to building a strong,
 talented and vertically integrated organization to successfully serve
 biotechnology and pharmaceutical customers throughout the world."
     Richey comes to Lumera with more than 25 years of experience in sales and
 marketing operations in the United States, Europe and Japan.  He has held
 senior executive positions in numerous rapid growth biotechnology success
 stories including LJL BioSystems (acquired by Molecular Devices), PerSeptive
 BioSystems (acquired by Applied Biosystems, now Applera), Pharmacia Biosensor
 (now BIAcore International), and Pharmacia Biotech (acquired by Amersham and
 recently by General Electric, today GE Healthcare).
     "As we receive orders for our first proteomics products, Jim's breadth of
 experience and history of achievement will undoubtedly allow him to make an
 immediate impact on the success of our company," said Tom Mino, chief
 executive officer.
     Dr. Campbell currently holds The West Endowed Professorship of Chemistry
 at the University of Washington, and is co-director of the University of
 Washington/Pacific Northwest National Laboratory Joint Institute for
 Nanotechnology.  He is currently Editor-in-Chief of the journal Surface
 Science and has served on the editorial boards of the Journals of Chemical
 Physics and of Cataysis.  During the course of his distinguished career he has
 received numerous awards and recognitions.
     "Dr. Campbell brings a uniquely integrated knowledge of nanoelectronics,
 surface chemistry and biodetection techniques," says Tom Mino, Lumera chief
 executive officer.  "We believe Dr. Campbell will have a meaningful impact as
 we work toward commercialization of key Lumera technologies."
     About Lumera
     Lumera is an emerging leader in the field of nanotechnology.  The company
 designs proprietary molecular structures and polymer compounds for a broad
 range of electro-optic, RF and specialty coating applications.  The company
 also has developed proprietary processes for fabricating such devices.  For
 more information, please visit
     Certain statements contained in this release are forward-looking
 statements that involve a number of risks and uncertainties.  Factors that
 could cause actual results to differ materially from those projected in the
 company's forward-looking statements include the following: market acceptance
 of our technologies and products; our ability to obtain financing; our
 financial and technical resources relative to those of our competitors; our
 ability to keep up with rapid technological change; government regulation of
 our technologies; our ability to enforce our intellectual property rights and
 protect our proprietary technologies; the ability to obtain additional
 contract awards and to develop partnership opportunities; the timing of
 commercial product launches; the ability to achieve key technical milestones
 in key products; and other risk factors identified from time to time in the
 company's SEC reports, including in its registrations statement on Form S-1,
 dated July 22, 2004 and its Quarterly Reports on Form 10-Q.

SOURCE Lumera Corporation